1.Research progress in calcium phosphate-based biomacromolecules antigen delivery system
Fangxin XIONG ; Zhangran DU ; Yadi TENG ; Min XUE ; Weiying XUN ; Zhongxiong FAN ; Jinyao LI
International Journal of Biomedical Engineering 2023;46(5):466-475
Nanometer materials have attracted much attention in the nanomedical field due to their unique physicochemical properties. Calcium phosphate nanoparticles have many advantages, such as non-toxicity, unique biomolecular protection, good biodegradability, and good biocompatibility. It has been widely studied as an ideal delivery system for biomacromolecules. In this review paper, the synthesis methods of calcium phosphate nanoparticles were summarized, including the conventional hydrothermal/solvothermal method and the aqueous wet chemical precipitation method. Moreover, the ways of binding calcium phosphate nanoparticles to biomacromolecule antigens were discussed from the perspectives of covalent and non-covalent binding, and their application in biomacromolecule delivery systems was described. The above review comments have important reference value for understanding the potential and application prospects of calcium phosphate nanoparticles in nanomedicine.
2. Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study
Chuan LIU ; Zicheng JIANG ; Chuxiao SHAO ; Hongguang ZHANG ; Hongmei YUE ; Zhenhuai CHEN ; Baoyi MA ; Weiying LIU ; Huihong HUANG ; Jie YANG ; Yan WANG ; Hongyan LIU ; Dan XU ; Jitao WANG ; Junyan YANG ; Hongqiu PAN ; Shengqiang ZOU ; Fujian LI ; Junqiang LEI ; Xun LI ; Qing HE ; Ye GU ; Xiaolong QI
Chinese Journal of Hepatology 2020;28(2):148-152
Objective:
To analyze the clinical characteristics of cases of novel coronavirus pneumonia and a preliminary study to explore the relationship between different clinical classification and liver damage.
Methods:
Consecutively confirmed novel coronavirus infection cases admitted to seven designated hospitals during January 23, 2020 to February 8, 2020 were included. Clinical classification (mild, moderate, severe, and critical) was carried out according to the diagnosis and treatment program of novel coronavirus pneumonia (Trial Fifth Edition) issued by the National Health Commission. The research data were analyzed using SPSS19.0 statistical software. Quantitative data were expressed as median (interquartile range), and qualitative data were expressed as frequency and rate.
Results:
32 confirmed cases that met the inclusion criteria were included. 28 cases were of mild or moderate type (87.50%), and four cases (12.50%) of severe or critical type. Four cases (12.5%) were combined with one underlying disease (bronchial asthma, coronary heart disease, malignant tumor, chronic kidney disease), and one case (3.13%) was simultaneously combined with high blood pressure and malignant tumor. The results of laboratory examination showed that the alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin (ALB), and total bilirubin (TBil) for entire cohort were 26.98 (16.88 ~ 46.09) U/L and 24.75 (18.71 ~ 31.79) U/L, 39.00 (36.20 ~ 44.20) g/L and 16.40 (11.34- ~ 21.15) mmol/L, respectively. ALT, AST, ALB and TBil of the mild or moderate subgroups were 22.75 (16.31- ~ 37.25) U/L, 23.63 (18.71 ~ 26.50) U/L, 39.70 (36.50 ~ 46.10) g/L, and 15.95 (11.34 ~ 20.83) mmol/L, respectively. ALT, AST, ALB and TBil of the severe or critical subgroups were 60.25 (40.88 ~ 68.90) U/L, 37.00 (20.88 ~ 64.45) U/L, 35.75 (28.68 ~ 42.00) g/L, and 20.50 (11.28 ~ 25.00) mmol/L, respectively.
Conclusion
The results of this multicenter retrospective study suggests that novel coronavirus pneumonia combined with liver damage is more likely to be caused by adverse drug reactions and systemic inflammation in severe patients receiving medical treatment. Therefore, liver function monitoring and evaluation should be strengthened during the treatment of such patients.